Overexpression of miR-302a can block CD44-mediated EGFR/RAS/RAF/MAPK and EGFR/PI3K/AKT signaling pathways and the cancer stem cells (CSC)-like properties in a dose-dependent manner, thereby restoring CRC sensitivity to Cetuximab [65]. Here, AKT1 is linked to cancer.